Coombe, Bender & Co’s Pfizer PFE Stock Holding History

Coombe, Bender & Co’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-11,584	Closed	-$334K	–	79
2023 Q4	$334K	Buy	+11,584	New	+$350K	0.21%	63
2023 Q2	–	Sell	-10,250	Closed	-$418K	–	80
2023 Q1	$418K	Buy	+10,250	New	+$443K	0.33%	53
2022 Q4	–	Sell	-10,237	Closed	-$448K	–	80
2022 Q3	$448K	Buy	10,237 +28	+0.3%	+$1.36K	0.4%	53
2022 Q2	$535K	Buy	+10,209	New	+$520K	0.45%	49

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Coombe, Bender & Co's PFE Position: Q1 2024 in Review

Coombe, Bender & Co sold out of Pfizer (PFE) in Q1 2024, closing a stake of 11,584 shares — an estimated $334K sold.

Coombe, Bender & Co first reported a position in PFE in Q2 2022 and held it in 4 quarters. The position peaked at $535K in Q2 2022. 2,882 funds tracked by Wall St. Rank hold PFE as of Q1 2024.

Coombe, Bender & Co reported no remaining Pfizer position as of Q1 2024 after selling out during the quarter.
Coombe, Bender & Co sold 11,584 Pfizer shares in Q1 2024, an estimated $334K.
Coombe, Bender & Co first reported a position in Pfizer in Q2 2022 and held it in 4 quarters.
Coombe, Bender & Co's Pfizer position peaked at $535K in Q2 2022.
2,882 funds tracked by Wall St. Rank held Pfizer as of Q1 2024.

Based on Coombe, Bender & Co's 13F filing for Q1 2024, filed 30 Apr 2024.